deficiency and means too little body iron to reach and meet the cellular iron need. [13, 14] In a randomized control trial, there was a catch-up growth in iron-deficient children after treating with iron. [15] Iron has a vital role in many metabolic processes such as DNA synthesis, oxygen and electron transport, [16] and also, it is a need for growth, development, normal cellular functioning, and the synthesis of some hormones and connective tissue. [13, 17] In human, both brain and body growth, especially during the phase of rapid infantile growth, requires relatively high energy supply and metabolism. Cellular energy metabolism is dependent on oxygen. Fe deficiency decreases oxygen-dependent cellular energy metabolism due to decreased heme and hemoglobin (Hb) synthesis, decreased red blood cells' (RBC) synthesis, and decreased RBC survival due to increased oxidative stress in RBC, Hb autoxidation, generation of toxic oxygen radicals' scrambling, and increased removal by the macrophage. Consequently, IDA leads to impaired cognitive abilities and defective linear growth. [18, 19] Infancy is a critical period of growth, which is may be affected by nutritional deficiencies. The magnitude of growth retardation in those who have IDA and degree of catch-up growth after iron therapy is unclear, and this is the purpose of this research to clarify more.
The aim of the study was to find any correlation between IDA and growth in children between 6 months and 5 years old.
MaterIals and Methods

Study design and patients
A cross-sectional, longitudinal, hospital-based study has been conducted at Raparin pediatric teaching hospital outpatient clinic in Erbil city/Kurdistan region/Iraq within 6 months between October 1, 2018, and March 1, 2019. Two sample groups have been selected: first group (anemic, cases) and second group (nonanemic, controls): each of them 50 age-and sex-matched cases using simple randomized sampling. All the cases included in the first and second group were assessed for anthropometric measures (weight, occipitofrontal circumference [OFC], and length) and plotted on Tanner et al.'s growth charts; [20] in addition, complete blood count was sent for all the cases and controls, and then, serum ferritin and serum iron levels for the anemic group were asessed. The anemic group was reassessed and followed up by all the anthropometric measures and investigations, while the control group was followed up only for anthropometric measures, follow-up was done for the anemic group after one, three, and 6 months, while the control group was followed up after three and 6 months.
Full history including nutritional intake was taken, and clinical examination was done for every single participant. Annualized growth velocity by measuring the growth rate in weight for 6 months was calculated. Body mass index (BMI) was calculated; normal population reference data were according to Tanner et al. [20] Inclusion criteria include clinical manifestation of anemia and low Hb level <11 g/dl, [2] low serum ferritin <12 µg/l, [21] low serum iron <25 µg/dl, [21] and microcytic hypochromic anemia on blood picture.
Children with chronic diseases such as malabsorption, cerebral palsy, liver and renal diseases, and other forms of anemia, also those with IDA not responding to iron therapy hematologically, all of them were excluded.
Ethical consideration
The protocol of the study was approved by the Research Ethics Committee of Kurdistan Board for Medical specialties before the beginning of the study. Informed consent (oral and written) was taken from all children caregivers.
Statistical analysis
Data were analyzed using the statistical package for social sciences version 24 (SPSS, IBM Company, Chicago, USA). Pearson correlation coefficient (r) was calculated to asses the strength of correlation between two numerical variables. Paired student t-test was used to compare variables before and after treatment. Independent sample t-test was used to compare variables of interest between cases and controls. P < 0.05 was considered as statistically significant.
results
One hundred children participated in the study, 50 were anemic and another half were control. For each of the groups, the equal number was included regarding sex of the participants: 25 males and 25 females. 30 preterms were assessed and followed up, as it has been shown in Table 1 . Table 2 which is about age distribution in part, shows no significant difference between cases and controls P > 0.05. Among all the growth parameters on the time of presentation, there was only significant difference between case and control in length/hight which has the mean and standard deviation of 77.2 ± 11.4 cm for the cases and 81.9 ± 11.4 cm for the control group, P = 0.044. Table 4 shows that there is no any difference between anemic and non anemic group regarding growth parameters, while there is a significant diference regarding growth velocity, i.e., anemic group had a faster growth than non anemic group, P < 0.0001. Figure 1 shows a strong positive significant correlation between growth velocity and serum ferritin, r 0.853, P < 0.0005 after giving iron therapy and correction of the anemia. This means that the more the serum ferritin, the more the growth velocity.
As shown in Figure 2 , serum ferritin concentration was correlated positively and significantly with BMI after treating anemia, r = 0.460, P = 0.001.
dIscussIon
The most common cause of hypochromic microcytic anemia is IDA, an important health problem worldwide mainly in developing countries. [22] Iron deficiency has many stages; the firsts stage is the depletion of ferritin which is the stored iron. second stage is deplesion of iron and transferrin but hemoglobin is still normal. The 3 rd stage is IDA which is characterized by low hemoglobin, hematocrit, and hypochromic microcytic picture on blood film. [17] The primary interest of this study was to know the effect of IDA on growth. In this cross-sectional study, we measured growth parameters in 50 children aged 19.1 ± 12.7 months with IDA before and for 6-month postiron therapy in comparison with normal controls. This study found that children with IDA were significantly shorter in comparison with age-and sex-matched controls before treatment, P < 0.05.
After treatment of the anemic group, their BMI increased significantly, P < 0.05, also the same significant increase for weight, length, and OFC with P < 0.0001 for all of them. After receiving therapy, serum ferritin was significantly correlated with growth velocity and BMI for the anemic group: r = 0.853 P < 0.0001 and r = 0.460 P < 0.001, respectively.
After treatment, the anemic group grew faster than non anemic group, P < 0.0001. Moreover, these results can tell us that iron is an essential element for normal growth. Iron has many important functions like; carring oxygen from the lung to the cells, transmission of an electron within the cells, acting as a cofactor for essential enzymatic reactions like synthesis of steroid hormones. [23] The exact mechanism of IDA effect on growth is not clear, but it may be through insulin-like growth factor-1 (IGF-1)-dependent mechanism which is a family of cytokines produced by the liver, osteoclasts, and many other cells; it is illustrated that IGF-1 concentration has an association with iron metabolism and protoporphyrin in children and adolescents. [24] Only few studies have investigated the effect of IDA on growth in children with IDA. Bandhu et al. studied the effects of IDA, and its treatment with iron, in schoolage children on growth parameters. Pretherapy values of IDA children were significantly lower for mid-arm circumference (MAC) and OFC in girls and for height and MAC in boys, when compared to the control group. Corrected hematological parameters were associated with significant improvement of height, weight, and MAC. Posttherapy, the anemic girls and boys had higher growth velocity than their respective control groups. [25] Soliman et al. measured anthropometric measures in 40 children with IDA pre-and post-treatment in comparison with normal controls. Before iron therapy, children with IDA were significantly shorter and had slower growth compared with age-matched controls. After treatment, their growth velocity, length standard deviation scores, and BMI increased significantly. Their growth velocity was correlated significantly with mean Hb concentration. [26] The results of our current study is close to the forementioned study results.
IDA can be prevented through primary and secondary prevention program, primary by iron supplementation of the on-risk groups and secondary prevention by early detection and treatment through special screening programs. [27, 28] The on-risk groups are prematurity and low birth weight, low socioeconomic status, excessive milk intake, early introduction of nonfortified whole cow's milk, prolonged bottle-feeding, and prolonged exclusive breastfeeding. conclusIon IDA in children, particularly during the period of rapid growth during the first 2 years of life, significantly impairs growth that can be corrected by adequate iron therapy. In view of the significant effect of IDA on growth, pediatricians, hematologists, endocrinologists, and other healthcare providers should strive to get rid from ID and its anemia through primary and secondary prevention.
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